



Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2022 [Japanese GAAP]

November 14, 2022
Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd.
 Securities code: 3902 URL <https://www.mdv.co.jp/>
 Representative: (Title) President (Name) Hiroyuki Iwasaki
 Inquiries: (Title) Executive Officer and General Manager of Corporate Planning Division (Name) Masahiro Kihara Tel: +81-3-5283-6911

Scheduled date to file quarterly report: November 14, 2022

Scheduled date to commence dividend payments: -

Preparation of supplementary material on quarterly financial results : Yes

Holding of quarterly financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the third quarter of the fiscal year ending December 31, 2022 (from January 1, 2022 to September 30, 2022)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Third quarter of FY ending December 31, 2022	4,327	-	1,168	-	1,159	-	776	-
Third quarter of FY ended December 31, 2021	3,952	25.3	1,037	32.6	1,036	32.2	699	32.7

(Note) Comprehensive income Third quarter of fiscal year ending December 31, 2022 774 million yen [-%]
 Third quarter of fiscal year ended December 31, 2021 717 million yen [36.1%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Third quarter of FY ending December 31, 2022	20.30	20.30
Third quarter of FY ended December 31, 2021	17.82	17.82

(Note) The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. Consolidated earnings for the 3rd quarter of the fiscal year ending December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of September 30, 2022 (3Q FY2022)	4,726	3,530	72.9
As of December 31, 2021 (FY2021)	5,534	4,205	75.1

(Reference) Equity As of September 30, 2022 3,445 million yen
 As of December 31, 2021 4,156 million yen

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
FY ended December 31, 2021	-	0.00	-	5.60	5.60
FY ending December 31, 2022	-	0.00	-		
FY ending December 31, 2022 (forecast)				6.00	6.00

(Note) Revision of the latest released dividend forecast : None

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	6,300	-	1,599	-	1,600	-	1,098	-	28.74

- (Notes) 1. Revision of the latest released earnings forecasts : None
 2. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. The above consolidated earnings forecasts therefore are the amount after applying such accounting standard and related implementation guidance, presenting no year-on-year changes.
 3. The Company purchased 763,400 treasury shares from January 1, 2022 to January 25, 2022 based on the resolution of the Board of Directors held on December 22, 2021. Basic earnings per share for the consolidated earnings forecasts takes into account the impact of the purchase of treasury shares.

* Notes

- (1) Changes in significant subsidiaries during the three months ended March 31, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation) : None

Newly included: - companies (Company name) , Excluded: - companies (Company name)

- (2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements : None

- (3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes
 (ii) Changes in accounting policies other than (i) above : None
 (iii) Changes in accounting estimates : None
 (iv) Restatement : None

(Notes) For more details, please refer to “(3) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes” on page 4 of the attached materials.

- (4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)	As of September 30, 2022	40,027,526 shares	As of December 31, 2021	40,027,526 shares
(ii) Number of treasury shares at the end of the period	As of September 30, 2022	1,830,678 shares	As of December 31, 2021	1,067,278 shares
(iii) Average number of shares outstanding during the period (cumulative quarterly period)	Third quarter of FY ending December 31, 2022	38,246,880 shares	Third quarter fiscal year ended December 31, 2021	39,253,806 shares

* Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.

* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.